Centre formulating R&D policy to bolster drug discovery

Blueprint to cover medical devices, include incentives for scientists, says official

August 06, 2020 08:01 am | Updated 01:20 pm IST - HYDERABAD

Local cure:  The central government has so far received 13 requests for setting up bulk drug parks .

Local cure: The central government has so far received 13 requests for setting up bulk drug parks .

The Centre will soon unveil a new Research & Development (R&D) policy to boost drug discovery and the manufacture of medical devices in the country.

Alongside, numerous production-linked incentives are also on the anvil, including to the scientists involved in the process, P.D. Vaghela, Secretary, Department of Pharmaceuticals, said on Wednesday.

The government proposes to set up three major manufacturing parks including one in Hyderabad, with an investment of ₹1,000 crore each to help drive import substitution of basic raw materials, active pharmaceutical ingredients (API) and the making of medical devices, Mr. Vaghela said.

Addressing a webinar to commemorate the 77th anniversary of CSIR-Indian Institute of Chemical Technology (IICT), the Secretary said there had to be renewed focus on bringing together research institutions, academia and the industry to identify new chemicals, update processes and discover new drug delivery systems.

‘Become millionaires’

He said current approval processes were archaic and that there was a dire need to strengthen institutions and recognise scientists’ role in new discoveries, and to help them commercialise the projects so they too can ‘become millionaires’.

The Centre has so far received 13 requests for setting up the bulk drug parks.

CSIR-DG Shekhar C. Mande said about 53 APIs had been identified for manufacture, of which 26 were being processed on a war footing, with results expected in 2-3 years.

Top News Today

Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in


Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.